Signature Equity Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Signature Equity Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674	Buy	+18	New	+$669	﹤0.01%	1390

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's CRNX Position: Q2 2026 in Review

Signature Equity Partners opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 18 shares worth $674. The stake represents ﹤0.01% of the portfolio and ranks #1390 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Signature Equity Partners held 18 shares of Crinetics Pharmaceuticals worth $674 as of Q2 2026.
Crinetics Pharmaceuticals was a new Signature Equity Partners position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1390 holding.
266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.